Pharmacovigilance & Risk Management

Overview

In the rapidly evolving landscape of metabolic health, the safety profile of a therapeutic candidate is as critical as its efficacy. Global regulatory bodies like the FDA and EMA demand rigorous, proactive oversight throughout the entire drug lifecycle. Protheragen provides an end-to-end pharmacovigilance & risk management service designed to safeguard patients and protect the commercial viability of your assets. By combining advanced signal detection algorithms with deep regulatory expertise, we transform complex safety data into actionable insights, ensuring that your benefit-risk profile remains favorable from the first-in-human trial to post-market surveillance.

Protecting Patient Safety, Ensuring Regulatory Integrity - Comprehensive PV Solutions for Metabolic Innovation

Protheragen offers a robust infrastructure to manage the complexities of global safety reporting and risk mitigation. We specialize in converting raw safety data into a strategic asset for regulatory success.

Workflow

Protheragen employs a standardized, data-centric workflow that synchronizes biostatistical rigor with clinical safety expertise. Our methodology focuses on preventative risk management, ensuring that potential safety hurdles are identified and addressed before they impact trial progression or market authorization.

Provide Contact Information to Design Tailored Programs Aligning Corporate Milestones.

Applications

• Cross-Border Clinical Trial Compliance

Establishing international pharmacovigilance systems that align with ICH E2A and E2F standards, ensuring that safety data from global sites is transmitted, evaluated, and reported to both the FDA and EMA in real-time.

• Signal Verification For New Drug Classes

Conducting deep-dive safety assessments for innovative incretin-based therapies or dual-agonists, focusing on high-priority areas such as pancreato-biliary health, medullary thyroid cancer risk, and diabetic retinopathy.

• Real-World Data (RWD) Safety Mining

Utilizing large-scale databases like FAERS or nationwide electronic health records to perform active post-marketing surveillance, identifying rare adverse events in diverse patient populations that were not evident during Phase III trials.

• Lifecycle Risk Management Plan (RMP) Development

Creating and maintaining living risk management plans (RMP) that evolve from phase I through phase IV, incorporating findings from the post-market & real-world study service to ensure long-term market access.

Advantages

Comprehensive Clinical Research Solutions

Protheragen provides an integrated safety and risk management ecosystem that bridges the gap between clinical data and regulatory expectations. Our service is designed to be a continuous loop of data collection, analysis, and mitigation, ensuring that safety is never a bottleneck in your development timeline. We recognize that metabolic drugs require specialized attention to specific system-organ classes, such as hepatobiliary, psychiatric, and cardiovascular health. By leveraging our interdisciplinary expertise in toxicology, epidemiology, and biostatistics, we help sponsors build a robust safety narrative that addresses the specific concerns of global health authorities. Our systems are fully scalable, supporting both small-scale phase I trials and massive, multinational phase IV observational studies.

Publication Data

Reach Out to Our Specialists for Dedicated Project Readiness Evaluations.

Customer Review

Frequently Asked Questions

1. What is a signal detection 'signal'?

   In pharmacovigilance, a signal is information that suggests a new potential causal association, or a new aspect of a known association, between an intervention and an event, which warrants further investigation.

2. What is the difference between a DSUR and a PBRER?

   A development safety update report (DSUR) is submitted during the clinical development phase to provide an annual, comprehensive overview of safety data for an investigational product across all ongoing trials and completed studies. In contrast, a periodic benefit-risk evaluation report (PBRER) is a post-marketing document that evaluates the benefit-risk balance of an approved product at defined intervals (e.g., every 6 months initially, then annually). While the DSUR focuses primarily on emerging safety findings during development, the PBRER integrates real-world exposure data, efficacy outcomes, and risk minimization measures to support continued regulatory authorization.

3. How do you ensure compliance with multiple global regulators simultaneously?

   We maintain a unified pharmacovigilance infrastructure that is natively mapped to the overlapping yet distinct requirements of the FDA, EMA, and NMPA. Our systems are built on ICH E2A, E2B, and E2F standards, ensuring that individual case safety reports (ICSRs), aggregate reports, and risk management plans (RMPs) are generated in formats accepted across jurisdictions. For region-specific mandates—such as the FDA's MedWatch forms, EMA's EVCTM/EVWEB submissions, or NMPA's localized reporting timelines—we deploy automated workflow triggers and dedicated regional PV leads. This dual-layer approach (global standardization + local regulatory nuance) minimizes administrative duplication while ensuring that every submission meets its respective deadline and format requirements.

4. How do you handle expedited reporting?

   We maintain a 24/7 safety intake system and utilize automated workflows to ensure that all serious unexpected adverse reactions (SUSARs) are reported to the relevant authorities within the mandatory 7 or 15-day windows.

Protheragen is dedicated to ensuring that your therapeutic innovations are supported by the highest standards of safety and compliance. Whether you are building a global safety database or seeking assistance in other areas, our PV experts are ready to assist. Contact us today to discuss a customized risk management strategy for your program.